160 related articles for article (PubMed ID: 38421473)
1. Pancreatic injury in patients treated with immune checkpoint inhibitors: a retrospective multicenterstudy.
Nagao K; Sakai A; Tsumura H; Iemoto T; Hirata Y; Hori H; Ogisu K; Kakuyama S; Ikegawa T; Hirata T; Ezaki T; Furumatsu K; Yamanaka K; Kato T; Fujigaki S; Tanaka H; Yagi Y; Tanaka T; Kobayashi T; Masuda A; Shiomi H; Kodama Y
J Gastroenterol; 2024 May; 59(5):424-433. PubMed ID: 38421473
[TBL] [Abstract][Full Text] [Related]
2. Incidence of Pancreatic Injury and Pancreatitis in Patients Treated With Immune Checkpoint Inhibitors.
Hori Y; Naitoh I; Naiki-Ito A; Kawai T; Yoshida M; Kato A; Kachi K; Sahashi H; Adachi A; Toyohara T; Kito Y; Yamamoto T; Takahashi S; Kataoka H
Clin Transl Gastroenterol; 2024 Apr; 15(4):e00667. PubMed ID: 38088372
[TBL] [Abstract][Full Text] [Related]
3. Pancreatitis and Hyperlipasemia in the Setting of Immune Checkpoint Inhibitor Therapy.
Townsend MJ; Liu M; Giobbie-Hurder A; Sack JS; LeBoeuf NR; Hodi FS; McNabb-Baltar J; Grover S
J Natl Compr Canc Netw; 2023 Aug; 21(8):831-840.e3. PubMed ID: 37549912
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury.
Abu-Sbeih H; Tang T; Lu Y; Thirumurthi S; Altan M; Jazaeri AA; Dadu R; Coronel E; Wang Y
J Immunother Cancer; 2019 Feb; 7(1):31. PubMed ID: 30728076
[TBL] [Abstract][Full Text] [Related]
5. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis.
Zhao Z; Zhang W; Pang L; Zeng L; Liu S; Liu J
Front Immunol; 2023; 14():1166299. PubMed ID: 37359551
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic involvement due to immune checkpoint inhibitors: a proposed classification.
Ashkar M; Chandra S; Vege SS; Takahashi H; Takahashi N; McWilliams RR
Cancer Immunol Immunother; 2023 Apr; 72(4):895-901. PubMed ID: 36161510
[TBL] [Abstract][Full Text] [Related]
8. Type 3 autoimmune pancreatitis (immune checkpoint inhibitor-induced pancreatitis).
Sayed Ahmed A; Abreo M; Thomas A; Chari ST
Curr Opin Gastroenterol; 2022 Sep; 38(5):516-520. PubMed ID: 35881977
[TBL] [Abstract][Full Text] [Related]
9. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
[TBL] [Abstract][Full Text] [Related]
10. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
Grimmelmann I; Momma M; Zimmer L; Hassel JC; Heinzerling L; Pföhler C; Loquai C; Ruini C; Utikal J; Thoms KM; Kähler KC; Eigentler T; Herbst RA; Meier F; Debus D; Berking C; Kochanek C; Ugurel S; Gutzmer R;
Eur J Cancer; 2021 May; 149():1-10. PubMed ID: 33812141
[TBL] [Abstract][Full Text] [Related]
11. Hepatobiliary and Pancreatic Adverse Events.
Zhang HC; Wang LS; Miller E
Adv Exp Med Biol; 2021; 1342():339-355. PubMed ID: 34972973
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis.
Zhang T; Wang Y; Shi C; Liu X; Lv S; Wang X; Li W
Front Pharmacol; 2022; 13():955701. PubMed ID: 36133806
[No Abstract] [Full Text] [Related]
13. Imaging findings of immune checkpoint inhibitor associated pancreatitis.
Das JP; Postow MA; Friedman CF; Do RK; Halpenny DF
Eur J Radiol; 2020 Oct; 131():109250. PubMed ID: 32905952
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events.
Nizam A; Rader RK; Tzeng A; Wei W; Sheng IY; Martin A; Wee CE; Gilligan TD; Gupta S; Ornstein MC
Clin Genitourin Cancer; 2024 Apr; 22(2):368-379. PubMed ID: 38245437
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitor-related Pancreatitis: A Case Series, Review of the Literature and an Expert Opinion.
Kramer S; van Hee K; Blokzijl H; van der Heide F; Visschedijk MC
J Immunother; 2023 Sep; 46(7):271-275. PubMed ID: 37216403
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic adverse events in patients treated with immune checkpoint inhibitors.
Hana C; Rehman T; Park K; Carracedo Uribe C; Aung PP; Hunis B; Salzberg M; Zikria J; Hussein A
JGH Open; 2023 Mar; 7(3):204-207. PubMed ID: 36968572
[TBL] [Abstract][Full Text] [Related]
17. Exocrine Pancreatic Insufficiency Induced by Immune Checkpoint Inhibitors.
Satish D; Lin IH; Flory J; Gerdes H; Postow MA; Faleck DM
Oncologist; 2023 Dec; 28(12):1085-1093. PubMed ID: 37285223
[TBL] [Abstract][Full Text] [Related]
18. Case Report: Nivolumab-Induced Autoimmune Pancreatitis.
Goyal P; Moyers JT; Elgohary BG; Hammami MB
J Immunother Precis Oncol; 2021 Nov; 4(4):208-211. PubMed ID: 35665025
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study.
Ladouceur A; Barnetche T; Mouterde G; Tison A; Bitoun S; Prey S; Dutriaux C; Gerard E; Pham-Ledard A; Beylot-Barry M; Zysman M; Veillon R; Domblides C; Daste A; Gross-Goupil M; Sionneau B; Lefort F; Larroquette M; Richez C; Truchetet ME; Schaeverbeke T; Kostine M
RMD Open; 2023 Nov; 9(4):. PubMed ID: 38030233
[TBL] [Abstract][Full Text] [Related]
20. Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience.
da Silva JA; Falcão D; Cardoso C; Pires AL; Araújo A; Castro-Poças F
Ann Hepatol; 2021 Dec; 26():100561. PubMed ID: 34653687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]